Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Walgreens has released the COVID-19 Pulse Check study, surveying over 1,000 seniors aged 55 and older in the U.S. The findings reveal that 42% of seniors are less socially active than pre-pandemic levels, with 20% feeling lonelier. Key concerns include a significant worry about socializing safely, particularly among the Black senior community, where 39% report feeling socially isolated. The report indicates that 70% of seniors feel more confident socializing around vaccinated individuals. Walgreens is promoting Seniors Day discounts and offering services like at-home COVID-19 tests and vaccination support during these events to help seniors regain confidence in social interactions.
Walgreens Boots Alliance (WBA) has announced a quarterly dividend of 48 cents per share, maintaining the same amount as the previous quarter and reflecting a 0.5% increase from last year. This dividend is scheduled to be paid on June 12, 2023, to stockholders recorded by May 19, 2023. WBA has a strong dividend history, having paid dividends for 362 consecutive quarters and raised them for 47 consecutive years. The company operates approximately 13,000 locations across the U.S., Europe, and Latin America, employing over 325,000 people and playing a significant role in the healthcare ecosystem. WBA is also recognized for its sustainability efforts and is part of the Dow Jones Sustainability Indices.
Walgreens and Prothena have announced a collaboration to enhance patient recruitment for Prothena's PRX012, a potential Alzheimer’s treatment currently in the ASCENT-2 clinical trial. Walgreens will utilize its extensive network and healthcare capabilities to identify suitable candidates, focusing on underserved communities. This trial has received Fast Track designation from the FDA, indicating its potential significance in addressing Alzheimer’s disease, which affects over 6.5 million Americans aged 65 and older. The partnership aims to create a more diverse patient population for the trial, aligning with the ENACT Act to improve inclusivity in Alzheimer’s research. Key topline data from ongoing Phase 1 studies is expected by the end of 2023.